Role of image-guided vascular intervention in therapeutic angiogenesis translational research

References

• Zerhouni E. Medicine. The NIH Roadmap. Science302(5642), 63–72 (2003).
   PubMed Web of Science ®Google Scholar
• Hirsch AT, Criqui MH, Treat-Jacobson D et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA286(11), 1317–1324 (2001).
   PubMed Web of Science ®Google Scholar
• Kannel WB, McGee DL. Update on some epidemiologic features of intermittent claudication: the Framingham Study. J. Am. Geriatr. Soc.33(1), 13–18 (1985).
   PubMed Web of Science ®Google Scholar
• Dormandy J, Heeck L, Vig S. The natural history of claudication: risk to life and limb. Semin. Vasc. Surg.12(2), 123–137 (1999).
   PubMedGoogle Scholar
• Albers M, Fratezi AC, De Luccia N. Assessment of quality of life of patients with severe ischemia as a result of infrainguinal arterial occlusive disease. J. Vasc. Surg.16(1), 54–59 (1992).
   PubMed Web of Science ®Google Scholar
• McDermott MM, Liu K, Greenland P et al. Functional decline in peripheral arterial disease: associations with the ankle brachial index and leg symptoms. JAMA292(4), 453–461 (2004).
   PubMed Web of Science ®Google Scholar
• Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J. Vasc. Surg.31(1 Pt 2), S1–S296 (2000).
   Google Scholar
• Hirsch AT, Haskal ZJ, Hertzer NR et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation113(11), e463–e654 (2006).
   PubMed Web of Science ®Google Scholar
• Hankey GJ, Norman PE, Eikelboom JW. Medical treatment of peripheral arterial disease. JAMA295(5), 547–553 (2006).
   PubMed Web of Science ®Google Scholar
• Dawson DL, Cutler BS, Hiatt WR et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am. J. Med.109(7), 523–530 (2000).
   PubMed Web of Science ®Google Scholar
• Money SR, Herd JA, Isaacsohn JL et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J. Vasc. Surg.27(2), 267–275 (1998).
   PubMed Web of Science ®Google Scholar
• Strandness DE Jr, Dalman RL, Panian S et al. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vasc. Endovascular Surg.36(2), 83–91 (2002).
   PubMedGoogle Scholar
• Dawson DL, Cutler BS, Meissner MH, Strandness DE Jr. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation98(7), 678–686 (1998).
   PubMed Web of Science ®Google Scholar
• Beebe HG, Dawson DL, Cutler BS et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch. Intern. Med.159(17), 2041–2050 (1999).
   PubMed Web of Science ®Google Scholar
• Mohler ER 3rd, Beebe HG, Salles-Cuhna S et al. Effects of cilostazol on resting ankle pressures and exercise-induced ischemia in patients with intermittent claudication. Vasc. Med.6(3), 151–156 (2001).
   PubMed Web of Science ®Google Scholar
• Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. JAMA274(12), 975–980 (1995).
   PubMed Web of Science ®Google Scholar
• Nehler MR, Hiatt WR. Exercise therapy for claudication. Ann. Vasc. Surg.13(1), 109–114 (1999).
   PubMed Web of Science ®Google Scholar
• Treesak C, Kasemsup V, Treat-Jacobson D, Nyman JA, Hirsch AT. Cost-effectiveness of exercise training to improve claudication symptoms in patients with peripheral arterial disease. Vasc. Med.9(4), 279–285 (2004).
   PubMed Web of Science ®Google Scholar
• Bakal CW. Advances in imaging technology and the growth of vascular and interventional radiology: a brief history. J. Vasc. Interv. Radiol.14(7), 855–860 (2003).
   PubMed Web of Science ®Google Scholar
• Liddell RP, Weiss CR, Hofmann LV. Therapeutic angiogenesis: the next frontier for interventional radiology. Tech. Vasc. Interv. Radiol.7(1), 40–48 (2004).
   PubMedGoogle Scholar
• Ito WD, Arras M, Scholz D et al. Angiogenesis but not collateral growth is associated with ischemia after femoral artery occlusion. Am. J. Physiol.273(3 Pt 2), H1255–H1265 (1997).
   Google Scholar
• Schaper W, Scholz D. Factors regulating arteriogenesis. Arterioscler. Thromb. Vasc. Biol.23(7), 1143–1151 (2003).
   PubMed Web of Science ®Google Scholar
• Hershey JC, Baskin EP, Glass JD et al. Revascularization in the rabbit hindlimb: dissociation between capillary sprouting and arteriogenesis. Cardiovasc. Res.49(3), 618–625 (2001).
   PubMed Web of Science ®Google Scholar
• Heil M, Eitenmuller I, Schmitz-Rixen T, Schaper W. Arteriogenesis versus angiogenesis: similarities and differences. J. Cell. Mol. Med.10(1), 45–55 (2006).
   PubMed Web of Science ®Google Scholar
• Pipp F, Boehm S, Cai WJ et al. Elevated fluid shear stress enhances postocclusive collateral artery growth and gene expression in the pig hind limb. Arterioscler. Thromb. Vasc. Biol.24(9), 1664–1668 (2004).
   PubMed Web of Science ®Google Scholar
• Eitenmuller I, Volger O, Kluge A et al. The range of adaptation by collateral vessels after femoral artery occlusion. Circ. Res.99(6), 656–662 (2006).
   PubMed Web of Science ®Google Scholar
• Losordo DW, Dimmeler S. Therapeutic angiogenesis and vasculogenesis for ischemic disease. Part I: angiogenic cytokines. Circulation109(21), 2487–2491 (2004).
   PubMed Web of Science ®Google Scholar
• Rajagopalan S, Mohler ER 3rd, Lederman RJ et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a Phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation108(16), 1933–1938 (2003).
   PubMed Web of Science ®Google Scholar
• Lederman RJ, Mendelsohn FO, Anderson RD et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet359(9323), 2053–2058 (2002).
   PubMed Web of Science ®Google Scholar
• Makinen K, Manninen H, Hedman M et al. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded Phase II study. Mol. Ther.6(1), 127–133 (2002).
   PubMed Web of Science ®Google Scholar
• Hughes GC, Annex BH. Angiogenic therapy for coronary artery and peripheral arterial disease. Expert Rev. Cardiovasc. Ther.3(3), 521–535 (2005).
   PubMedGoogle Scholar
• Ennett AB, Kaigler D, Mooney DJ. Temporally regulated delivery of VEGF in vitro and in vivo.J. Biomed. Mater. Res.79(1), 176–184 (2006).
   Google Scholar
• Wolff JA, Malone RW, Williams P et al. Direct gene transfer into mouse muscle in vivo.Science247(4949), 1465–1468 (1990).
   PubMed Web of Science ®Google Scholar
• Wolff JA, Budker V. The mechanism of naked DNA uptake and expression. Adv. Genet.54, 3–20 (2005).
   PubMed Web of Science ®Google Scholar
• Gounis MJ, Spiga MG, Graham RM et al. Angiogenesis is confined to the transient period of VEGF expression that follows adenoviral gene delivery to ischemic muscle. Gene Ther.12(9), 762–771 (2005).
   PubMed Web of Science ®Google Scholar
• Dor Y, Djonov V, Abramovitch R et al. Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J.21(8), 1939–1947 (2002).
   PubMed Web of Science ®Google Scholar
• Ozawa CR, Banfi A, Glazer NL et al. Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. J. Clin. Invest.113(4), 516–527 (2004).
   PubMed Web of Science ®Google Scholar
• Epstein SE, Stabile E, Kinnaird T et al. Janus phenomenon: the interrelated tradeoffs inherent in therapies designed to enhance collateral formation and those designed to inhibit atherogenesis. Circulation109(23), 2826–2831 (2004).
   PubMed Web of Science ®Google Scholar
• Celletti FL, Waugh JM, Amabile PG et al. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat. Med.7(4), 425–429 (2001).
   PubMed Web of Science ®Google Scholar
• Shams N, Ianchulev T. Role of vascular endothelial growth factor in ocular angiogenesis. Ophthalmol. Clin. North Am.19(3), 335–344 (2006).
   PubMedGoogle Scholar
• Semenza GL. Involvement of hypoxia-inducible factor 1 in pulmonary pathophysiology. Chest128(Suppl. 6), S592–S594 (2005).
   PubMed Web of Science ®Google Scholar
• Lee CW, Stabile E, Kinnaird T et al. Temporal patterns of gene expression after acute hindlimb ischemia in mice: insights into the genomic program for collateral vessel development. J. Am. Coll. Cardiol.43(3), 474–482 (2004).
   PubMed Web of Science ®Google Scholar
• Kondoh K, Koyama H, Miyata T et al. Conduction performance of collateral vessels induced by vascular endothelial growth factor or basic fibroblast growth factor. Cardiovasc. Res.61(1), 132–142 (2004).
   PubMed Web of Science ®Google Scholar
• Cao R, Brakenhielm E, Pawliuk R et al. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat. Med.9(5), 604–613 (2003).
   PubMed Web of Science ®Google Scholar
• Nakagami H, Morishita R, Maeda K et al. Adipose tissue-derived stromal cells as a novel option for regenerative cell therapy. J. Atheroscler. Thromb.13(2), 77–81 (2006).
   PubMed Web of Science ®Google Scholar
• Iwase T, Nagaya N, Fujii T et al. Comparison of angiogenic potency between mesenchymal stem cells and mononuclear cells in a rat model of hindlimb ischemia. Cardiovasc. Res.66(3), 543–551 (2005).
   PubMed Web of Science ®Google Scholar
• Kinnaird T, Stabile E, Burnett MS et al. Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation109(12), 1543–1549 (2004).
   PubMed Web of Science ®Google Scholar
• Losordo DW, Dimmeler S. Therapeutic angiogenesis and vasculogenesis for ischemic disease: part II: cell-based therapies. Circulation109(22), 2692–2697 (2004).
   PubMed Web of Science ®Google Scholar
• Rehman J, Traktuev D, Li J et al. Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation109(10), 1292–1298 (2004).
   PubMed Web of Science ®Google Scholar
• Nakagami H, Maeda K, Morishita R et al. Novel autologous cell therapy in ischemic limb disease through growth factor secretion by cultured adipose tissue-derived stromal cells. Arterioscler. Thromb. Vasc. Biol.25(12), 2542–2547 (2005).
   PubMed Web of Science ®Google Scholar
• Asahara T, Kawamoto A. Endothelial progenitor cells for postnatal vasculogenesis. Am. J. Physiol.287(3), C572–C579 (2004).
   PubMed Web of Science ®Google Scholar
• Schachinger V, Erbs S, Elsasser A et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N. Engl. J. Med.355(12), 1210–1221 (2006).
   PubMed Web of Science ®Google Scholar
• Lunde K, Solheim S, Aakhus S et al. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N. Engl. J. Med.355(12), 1199–1209 (2006).
   PubMed Web of Science ®Google Scholar
• Seeger FH, Tonn T, Krzossok N, Zeiher AM, Dimmeler S. Cell isolation procedures matter: a comparison of different isolation protocols of bone marrow mononuclear cells used for cell therapy in patients with acute myocardial infarction. Eur. Heart J.28(6), 766–772 (2007).
   PubMed Web of Science ®Google Scholar
• Tepper OM, Galiano RD, Capla JM et al. Human endothelial progenitor cells from Type 2 diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation106(22), 2781–2786 (2002).
   PubMed Web of Science ®Google Scholar
• Waltenberger J. Impaired collateral vessel development in diabetes: potential cellular mechanisms and therapeutic implications. Cardiovasc. Res.49(3), 554–560 (2001).
   PubMed Web of Science ®Google Scholar
• Le Blanc K. Immunomodulatory effects of fetal and adult mesenchymal stem cells. Cytotherapy5(6), 485–489 (2003).
   PubMed Web of Science ®Google Scholar
• McIntosh K, Zvonic S, Garrett S et al. The immunogenicity of human adipose-derived cells: temporal changes in vitro.Stem Cells24(5), 1246–1253 (2006).
   PubMed Web of Science ®Google Scholar
• Nauta AJ, Westerhuis G, Kruisselbrink AB et al. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood108(6), 2114–2120 (2006).
   PubMed Web of Science ®Google Scholar
• Horwitz EM, Prockop DJ, Fitzpatrick LA et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat. Med.5(3), 309–313 (1999).
   PubMed Web of Science ®Google Scholar
• Li J, Zhang YP, Kirsner RS. Angiogenesis in wound repair: angiogenic growth factors and the extracellular matrix. Microsc. Res. Tech.60(1), 107–114 (2003).
   PubMed Web of Science ®Google Scholar
• Tang GL, Chang DS, Sarkar R, Wang R, Messina LM. The effect of gradual or acute arterial occlusion on skeletal muscle blood flow, arteriogenesis, and inflammation in rat hindlimb ischemia. J. Vasc. Surg.41(2), 312–320 (2005).
   PubMed Web of Science ®Google Scholar
• Baffour R, Garb JL, Kaufman J et al. Angiogenic therapy for the chronically ischemic lower limb in a rabbit model. J. Surg. Res.93(2), 219–229 (2000).
   PubMed Web of Science ®Google Scholar
• Liddell RP, Patel TH, Weiss CR et al. Endovascular model of rabbit hindlimb ischemia: a platform to evaluate therapeutic angiogenesis. J. Vasc. Interv. Radiol.16(7), 991–998 (2005).
   PubMed Web of Science ®Google Scholar
• Weinberg PD, Ross Ethier C. Twenty-fold difference in hemodynamic wall shear stress between murine and human aortas. J. Biomech.40(7) 1594–1589 (2006).
   PubMed Web of Science ®Google Scholar
• Patel TH, Kimura H, Weiss CR, Semenza GL, Hofmann LV. Constitutively active HIF-1α improves perfusion and arterial remodeling in an endovascular model of limb ischemia. Cardiovasc. Res.68(1), 144–154 (2005).
   PubMed Web of Science ®Google Scholar
• Nikol S, Armeanu S, Engelmann MG et al. Evaluation of endovascular techniques for creating a porcine femoral artery occlusion model. J. Endovasc. Ther.8(4), 401–407 (2001).
   PubMed Web of Science ®Google Scholar
• van Weel V, de Vries M, Voshol PJ et al. Hypercholesterolemia reduces collateral artery growth more dominantly than hyperglycemia or insulin resistance in mice. Arterioscler. Thromb. Vasc. Biol.26(6), 1383–1390 (2006).
   PubMed Web of Science ®Google Scholar
• de Lussanet QG, van Golde JC, Beets-Tan RG et al. Dynamic contrast-enhanced MRI of muscle perfusion combined with MR angiography of collateral artery growth in a femoral artery ligation model. NMR Biomed. (2007) (Epub ahead of print).
   PubMedGoogle Scholar
• Isbell DC, Epstein FH, Zhong X et al. Calf muscle perfusion at peak exercise in peripheral arterial disease: measurement by first-pass contrast-enhanced magnetic resonance imaging. J. Magn. Reson. Imaging (2007).
   PubMedGoogle Scholar
• Kiessling F, Morgenstern B, Zhang C. Contrast agents and applications to assess tumor angiogenesis in vivo by magnetic resonance imaging. Curr. Med. Chem.14(1), 77–91 (2007).
   PubMed Web of Science ®Google Scholar
• Foster-Gareau P, Heyn C, Alejski A, Rutt BK. Imaging single mammalian cells with a 1.5 T clinical MRI scanner. Magn. Reson. Med.49(5), 968–971 (2003).
   PubMed Web of Science ®Google Scholar
• Dodd SJ, Williams M, Suhan JP et al. Detection of single mammalian cells by high-resolution magnetic resonance imaging. Biophys. J.76(1 Pt 1), 103–109 (1999).
   PubMed Web of Science ®Google Scholar
• Cunningham CH, Arai T, Yang PC et al. Positive contrast magnetic resonance imaging of cells labeled with magnetic nanoparticles. Magn. Reson. Med.53(5), 999–1005 (2005).
   PubMed Web of Science ®Google Scholar
• Arbab AS, Yocum GT, Kalish H et al. Efficient magnetic cell labeling with protamine sulfate complexed to ferumoxides for cellular MRI. Blood104(4), 1217–1223 (2004).
   PubMed Web of Science ®Google Scholar
• de Vries IJ, Lesterhuis WJ, Barentsz JO et al. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat. Biotechnol.23(11), 1407–1413 (2005).
   PubMed Web of Science ®Google Scholar
• Anderson SA, Glod J, Arbab AS et al. Noninvasive MR imaging of magnetically labeled stem cells to directly identify neovasculature in a glioma model. Blood105(1), 420–425 (2005).
   PubMed Web of Science ®Google Scholar
• Kraitchman DL, Heldman AW, Atalar E et al.In vivo magnetic resonance imaging of mesenchymal stem cells in myocardial infarction. Circulation107(18), 2290–2293 (2003).
   PubMed Web of Science ®Google Scholar
• Kraitchman DL, Tatsumi M, Gilson WD et al. Dynamic imaging of allogeneic mesenchymal stem cells trafficking to myocardial infarction. Circulation112(10), 1451–1461 (2005).
   PubMed Web of Science ®Google Scholar
• Bos C, Delmas Y, Desmouliere A et al.In vivo MR imaging of intravascularly injected magnetically labeled mesenchymal stem cells in rat kidney and liver. Radiology233(3), 781–789 (2004).
   PubMed Web of Science ®Google Scholar
• Cahill KS, Gaidosh G, Huard J et al. Noninvasive monitoring and tracking of muscle stem cell transplants. Transplantation78(11), 1626–1633 (2004).
   PubMed Web of Science ®Google Scholar
• Dick AJ, Guttman MA, Raman VK et al. Magnetic resonance fluoroscopy allows targeted delivery of mesenchymal stem cells to infarct borders in Swine. Circulation108(23), 2899–2904 (2003).
   PubMed Web of Science ®Google Scholar
• Cyrus T, Winter PM, Caruthers SD, Wickline SA, Lanza GM. Magnetic resonance nanoparticles for cardiovascular molecular imaging and therapy. Expert Rev. Cardiovasc. Ther.3(4), 705–715 (2005).
   PubMedGoogle Scholar
• Frank JA, Miller BR, Arbab AS et al. Clinically applicable labeling of mammalian and stem cells by combining superparamagnetic iron oxides and transfection agents. Radiology228(2), 480–487 (2003).
   PubMed Web of Science ®Google Scholar
• Bulte JW, Arbab AS, Douglas T, Frank JA. Preparation of magnetically labeled cells for cell tracking by magnetic resonance imaging. Methods Enzymol.386, 275–299 (2004).
   Google Scholar
• Arbab AS, Jordan EK, Wilson LB et al.In vivo trafficking and targeted delivery of magnetically labeled stem cells. Hum. Gene Ther.15(4), 351–360 (2004).
   PubMed Web of Science ®Google Scholar
• Arbab AS, Yocum GT, Rad AM et al. Labeling of cells with ferumoxides-protamine sulfate complexes does not inhibit function or differentiation capacity of hematopoietic or mesenchymal stem cells. NMR Biomed.18(8), 553–559 (2005).
   PubMed Web of Science ®Google Scholar
• Genove G, DeMarco U, Xu H, Goins WF, Ahrens ET. A new transgene reporter for in vivo magnetic resonance imaging. Nat. Med.11(4), 450–454 (2005).
   PubMed Web of Science ®Google Scholar
• Cao F, Lin S, Xie X et al.In vivo visualization of embryonic stem cell survival, proliferation, and migration after cardiac delivery. Circulation113(7), 1005–1014 (2006).
   PubMed Web of Science ®Google Scholar
• Wu JC, Inubushi M, Sundaresan G, Schelbert HR, Gambhir SS. Positron emission tomography imaging of cardiac reporter gene expression in living rats. Circulation106(2), 180–183 (2002).
   PubMedGoogle Scholar
• Wagner B, Anton M, Nekolla SG et al. Noninvasive characterization of myocardial molecular interventions by integrated positron emission tomography and computed tomography. J. Am. Coll. Cardiol.48(10), 2107–2115 (2006).
   PubMed Web of Science ®Google Scholar
• Cai W, Chen K, Mohamedali KA et al. PET of vascular endothelial growth factor receptor expression. J. Nucl. Med.47(12), 2048–2056 (2006).
   PubMed Web of Science ®Google Scholar
• Cai W, Zhang X, Wu Y, Chen X. A thiol-reactive 18F-labeling agent, N-[2-(4–18F-fluorobenzamido)ethyl] maleimide, and synthesis of RGD peptide-based tracer for PET imaging of αv β3 integrin expression. J. Nucl. Med.47(7), 1172–1180 (2006).
   PubMed Web of Science ®Google Scholar
• Zhang X, Chen X. Preparation and characterization of 99mTc(CO)3-BPy-RGD complex as αv β3 integrin receptor-targeted imaging agent. Appl. Radiat. Isot.65(1), 70–78 (2007).
   PubMed Web of Science ®Google Scholar
• Fani M, Psimadas D, Zikos C et al. Comparative evaluation of linear and cyclic 99mTc-RGD peptides for targeting of integrins in tumor angiogenesis. Anticancer Res.26(1A), 431–434 (2006).
   PubMed Web of Science ®Google Scholar
• Beer AJ, Haubner R, Goebel M et al. Biodistribution and pharmacokinetics of the αv β3-selective tracer 18F-galacto-RGD in cancer patients. J. Nucl. Med.46(8), 1333–1341 (2005).
   PubMed Web of Science ®Google Scholar
• Penuelas I, Mazzolini G, Boan JF et al. Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients. Gastroenterology128(7), 1787–1795 (2005).
   PubMed Web of Science ®Google Scholar
• Jacobs A, Voges J, Reszka R et al. Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas. Lancet358(9283), 727–729 (2001).
   PubMed Web of Science ®Google Scholar
• Ginsburg DS, Calos MP. Site-specific integration with phiC31 integrase for prolonged expression of therapeutic genes. Adv. Genet.54, 179–187 (2005).
   PubMed Web of Science ®Google Scholar